Natera, Inc. (NTRA)
NTRA Stock Price Chart
Explore Natera, Inc. interactive price chart. Choose custom timeframes to analyze NTRA price movements and trends.
NTRA Company Profile
Discover essential business fundamentals and corporate details for Natera, Inc. (NTRA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
1 Jul 2015
Employees
4.42k
Website
https://www.natera.comCEO
Steven Leonard Chapman
Description
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
NTRA Financial Timeline
Browse a chronological timeline of Natera, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.49, while revenue estimate is $661.24m.
Earnings released on 7 May 2026
EPS came in at -$0.56 falling short of the estimated -$0.54 by -3.28%, while revenue for the quarter reached $696.64m , beating expectations by +12.89%.
Earnings released on 26 Feb 2026
EPS came in at $0.35 surpassing the estimated -$0.51 by +168.35%, while revenue for the quarter reached $665.50m , beating expectations by +10.18%.
Earnings released on 6 Nov 2025
EPS came in at -$0.64 falling short of the estimated -$0.39 by -65.94%, while revenue for the quarter reached $592.18m , beating expectations by +15.33%.
Earnings released on 7 Aug 2025
EPS came in at -$0.74 falling short of the estimated -$0.62 by -20.24%, while revenue for the quarter reached $546.60m , beating expectations by +14.77%.
Earnings released on 8 May 2025
EPS came in at -$0.50 surpassing the estimated -$0.64 by +21.93%, while revenue for the quarter reached $501.83m , beating expectations by +12.46%.
Earnings released on 27 Feb 2025
EPS came in at -$0.41 falling short of the estimated -$0.38 by -7.57%, while revenue for the quarter reached $476.06m , beating expectations by +9.28%.
Earnings released on 12 Nov 2024
EPS came in at -$0.26 surpassing the estimated -$0.57 by +54.39%, while revenue for the quarter reached $439.76m , beating expectations by +21.67%.
Earnings released on 8 Aug 2024
EPS came in at -$0.30 surpassing the estimated -$0.69 by +56.52%, while revenue for the quarter reached $413.35m , beating expectations by +20.51%.
Earnings released on 9 May 2024
EPS came in at -$0.56 surpassing the estimated -$0.71 by +21.13%, while revenue for the quarter reached $367.74m , beating expectations by +16.26%.
Earnings released on 28 Feb 2024
EPS came in at -$0.64 surpassing the estimated -$0.73 by +12.33%, while revenue for the quarter reached $311.11m , beating expectations by +3.70%.
Earnings released on 8 Nov 2023
EPS came in at -$0.95 surpassing the estimated -$0.96 by +1.04%, while revenue for the quarter reached $268.31m , beating expectations by +3.53%.
Earnings released on 3 Aug 2023
EPS came in at -$0.97 surpassing the estimated -$1.09 by +11.01%, while revenue for the quarter reached $261.40m , beating expectations by +2.21%.
Earnings released on 9 May 2023
EPS came in at -$1.23 falling short of the estimated -$1.15 by -6.96%, while revenue for the quarter reached $241.76m , beating expectations by +6.19%.
Earnings released on 28 Feb 2023
EPS came in at -$1.37 surpassing the estimated -$1.42 by +3.52%, while revenue for the quarter reached $217.25m , beating expectations by +0.78%.
Earnings released on 8 Nov 2022
EPS came in at -$1.25 surpassing the estimated -$1.44 by +13.19%, while revenue for the quarter reached $210.64m , beating expectations by +1.93%.
Earnings released on 4 Aug 2022
EPS came in at -$1.50 matching the estimated -$1.50, while revenue for the quarter reached $198.20m , beating expectations by +2.34%.
Earnings released on 5 May 2022
EPS came in at -$1.45 surpassing the estimated -$1.48 by +2.03%, while revenue for the quarter reached $194.13m , missing expectations by -1.99%.
Earnings released on 24 Feb 2022
EPS came in at -$1.48 falling short of the estimated -$1.31 by -12.98%, while revenue for the quarter reached $173.03m , beating expectations by +2.42%.
Earnings released on 4 Nov 2021
EPS came in at -$1.63 falling short of the estimated -$1.27 by -28.35%, while revenue for the quarter reached $158.12m , beating expectations by +4.84%.
Earnings released on 5 Aug 2021
EPS came in at -$1.32 falling short of the estimated -$1.12 by -17.86%, while revenue for the quarter reached $142.03m , beating expectations by +9.50%.
NTRA Stock Performance
Access detailed NTRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
